NCT02979951

Fosfomycin I.v. for Treatment of Severely Infected Patients

An International, Multicentre, Non-comparative, Non-interventional, Prospective Clinical Registry to Evaluate the Clinical Outcome and Safety of the Treatment of Severely Infected Patients with Fosfomycin I.v.

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (estimated)
• Sponsor: Infectopharm Arzneimittel GmbH · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin, including patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infections, each as far as covered by the respective nationally relevant SmPC.

Conditions

• Bacterial Infections
• Bone Diseases, Infectious
• Osteomyelitis
• Central Nervous System Bacterial Infections
• Meningitis, Bacterial
• Encephalitis
• Brain Abscess
• Urinary Tract Infections
• Respiratory Tract Infections
• Pneumonia, Bacterial
• Skin Diseases, Bacterial
• Soft Tissue Infections
• Intraabdominal Infections
• Sepsis
• Bacteremia
• Endocarditis, Bacterial

Timeline

• Start date: 2016-12-01
• Primary completion: 2030-12-01
• Completion: 2030-12-01
• First posted: 2016-12-02
• Last updated: 2024-10-01

Locations

50 sites across 5 countries: Austria, Germany, Greece, Italy, United Kingdom